Evaluation of the Vivo Isar Stent System in Routine Clinical Practice
NCT ID: NCT06420505
Last Updated: 2024-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2023-11-29
2027-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
NCT06412250
Assessment of GORE® EXCLUDER® IBE Plus Stent Graft Performance in Patients Undergoing Endovascular Iliac Revascularization
NCT07304102
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
NCT03103620
The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus
NCT00235092
ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2
NCT05072730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Percutaneous Coronary Intervention
The Vivo ISAR is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide signed informed consent form.
* Male or non-pregnant female patient (Pregnancy status to be confirmed verbally from the female patient of reproductive age)
* Presentation with acute coronary syndrome or chronic coronary syndrome with stable angina or angina equivalent symptoms or with a positive noninvasive test for ischemia or evidence of a functionally significant coronary stenosis.
* Patient having social security number.
* Patient treated only with Vivo ISAR stent in case of single or multiple vessel stenting
Exclusion Criteria
* Having benefited from an angioplasty of ≤ 1 month with a stent other than Vivo ISAR.
* Planned elective surgery in next 6 months
* Cardiogenic shock/ hemodynamically unstable patients
* Concurrent medical condition with a life expectancy of less than 12 months
* History of cerebrovascular accident in the last 6 months.
* Vulnerable patient under guardianship or curatorship
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EVAMED
OTHER
Translumina GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thibault Lhermusier, Pr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Axium
Aix-en-Provence, , France
CHU CAEN
Caen, , France
Hôpital A. Schweitzer - GHCA
Colmar, , France
Clinique Louis Pasteur
Essey-lès-Nancy, , France
CH Haguenau
Haguenau, , France
CHU La Timone
Marseille, , France
Hopital Nord
Marseille, , France
HP Jacques Cartier
Massy, , France
Clinique Pont de Chaume
Montauban, , France
Hôpital Privé du Confluent
Nantes, , France
Polyclinique Les Fleurs
Ollioules, , France
APHP
Paris, , France
HP Claude Galien
Quincy-sous-Sénart, , France
CHU Reims
Reims, , France
Clinique Saint Hilaire
Rouen, , France
CHRU Strasbourg
Strasbourg, , France
CH de Bigorre
Tarbes, , France
Clinique Pasteur
Toulouse, , France
Chu Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
La Scala, Dr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRANSLUMINA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.